B+
Bull case
25%
Probability
Target price
$38.00
+38.7% vs current
ETON
EtonANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$31.00
+13.1% vs current
B-
Bear case
25%
Probability
Target price
$20.00
-27.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-30
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+58.5
Score
AI commentary
Sentiment is positive but still low-conviction. Primary filings and company releases show real operating progress: Q1 revenue and gross profit held up, HEMANGEOL relaunched, and IMPAVIDO adds another commercial asset. But the new deal structure is cash- and execution-intensive, analyst coverage is thin, and there is no reliable social or options confirmation, so this remains a launch-and-execution story rather than a clean valuation rerating.
RankAlpha Sentiment Codex - 2026-05-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystHEMANGEOL relaunch can prove out the next commercial rampMedium impact
Eton relaunched HEMANGEOL on May 1, and the 10-K shows the company paid a meaningful upfront amount, bought inventory, and owes an 8.0% royalty on net sales. The next few weeks matter for early fill and adoption read-through, because this launch adds real revenue potential but also adds commercialization cost and execution risk [#8-K-2026-05-01] [#10-K-2026-03-19].
2026-09-26eventIMPAVIDO U.S. commercialization rights add a delayed but material new assetMedium impact
On May 18, Eton entered a supply and distribution agreement that gives it U.S. commercialization rights to IMPAVIDO beginning September 26, 2026. The deal is economically meaningful, but Eton must fund sales and marketing, pay fixed fees, and share net sales with the supplier, so upside depends on successful launch execution [#8-K-2026-05-19].
2026-10-31catalystET-700 topline results remain the main second-half pipeline readoutHigh impact
Eton said the first patient was dosed in the ET-700 pilot study on April 27, with topline results expected in the second half of 2026 and a pivotal study in early 2027 if data are positive. This is the clearest development-stage upside lever, but it is still early proof-of-concept rather than late-stage de-risked data [#IR-2026-04-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-30 • Updated nightlySource: Internal modelMethodology